Leaflet ARTESYD 25mg tablets


Indicated for: chorea in Huntington disease

Route of administration: oral

Substance: tetrabenazine (VMAT2 inhibitor)

ATC: N07XX06 (Nervous system | Other nervous system drugs)

Tetrabenazine is a medication used for the treatment of movement disorders associated with Huntington's chorea and other hyperkinetic conditions. It works by reducing dopamine levels in the brain, helping to control involuntary movements.

The medication is taken orally, usually two to three times daily, as directed by a doctor. The dosage is gradually adjusted to minimize the risk of side effects.

Patients should be monitored for potential side effects, such as drowsiness, depression, or extrapyramidal symptoms. It is important for patients to inform their doctor of any unusual symptoms or the use of other medications.

Common side effects include drowsiness, fatigue, depression, and insomnia. In rare cases, severe reactions such as extrapyramidal symptoms or suicidal thoughts may occur. Patients should be informed of these risks before starting treatment.

General data about ARTESYD 25mg

  • Substance: tetrabenazine
  • Date of last drug list: 01-03-2022
  • Commercial code: W63073002
  • Concentration: 25mg
  • Pharmaceutical form: tablets
  • Quantity: 112
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
  • Holder: AOP ORPHAN PHARMACEUTICALS AG - AUSTRIA
  • Number: 9327/2016/02
  • Shelf life: 3 years